Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

NCT02296684 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Cancer of Head and Neck
Head and Neck Cancer
Neoplasms, Head and Neck
Carcinoma, Squamous Cell of Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma, Head and Neck

Interventions

BIOLOGICAL: MK-3475 (neoadjuvant)
PROCEDURE: Surgery
RADIATION: Intensity modulated radiation therapy
RADIATION: Image-guided radiation therapy
DRUG: Cisplatin
BIOLOGICAL: MK-3475 (adjuvant)
PROCEDURE: Peripheral blood

Sponsor

Washington University School of Medicine

Collaborators

[object Object]